When statins do not lower cholesterol enough, doctors often turn to other drugs. The question is which of those options works best.
Cardiologists trying to bring down LDL, or “bad,” cholesterol that can build up in the coronary arteries often weigh two long-established therapies. One is the injectable PCSK9 inhibitor evolocumab, marketed by Amgen as Repatha. The other is the oral cholesterol absorption inhibitor ezetimibe, now available as a generic and previously sold by Merck under the name Zetia. A new real-world evidence trial compared the two.
Repatha came out ahead.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Monthly
$39
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Annual
$399
Save 15%
11+ Users
Custom
Savings start at 25%!
2-10 Users
$300
Annually per user
To read the rest of this story subscribe to STAT+.
More from Digilifetrends
Customized meal delivery may help reduce blood pressure and blood sugar
Meals delivered to the home and tailored to medical needs were associated with improved blood pressure, blood sugar and overall diet quality in a small study.
2 min read · Published 2026-11-06Nighttime Foot Cramps? These Simple Moves Can Relieve Pain in 30 Seconds
You may be drifting off to sleep when a sudden burst of pain hits your foot, leaving you clutching it and trying to make the discomfort go away. Nighttime foot cramps can be…
3 min read · Published 2026-11-05Dandelion Tea Benefits: What It May Do for Your Health
Dandelion tea may offer several potential health benefits, from acting as a natural diuretic to supporting digestion.
3 min read · Published 2026-11-05